Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Bushnell

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The Annals of Thoracic Surgery|February 16, 2002
Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?Kemp H Kernstine, Kelley A Mclaughlin, Yusuf Menda, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2019
NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATEThomas A Hope, Amanda Abbott, Karen Colucci, et al.
Pancreas|July 29, 2010
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and CecumJ Philip Boudreaux, David S Klimstra, Manal M Hassan, et al.
Pancreas|October 21, 2016
Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine TumorsNancy Sharma, Boris G Naraev, Eric G Engelman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 11, 2018
<sup>90</sup>Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide TherapyYusuf Menda, Mark T Madsen, Thomas M O'Dorisio, et al.
Pancreas|April 17, 2013
Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumorsYusuf Menda, Laura L Boles Ponto, Michael K Schultz, et al.
Pancreas|July 29, 2010
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreasMatthew H Kulke, Lowell B Anthony, David L Bushnell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2017
Localization of Unknown Primary Site with <sup>68</sup>Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine TumorYusuf Menda, Thomas M O'Dorisio, James R Howe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2021
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATEJonathan R Strosberg, Rajaventhan Srirajaskanthan, Ghassan El-Haddad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
90Y-edotreotide for metastatic carcinoid refractory to octreotideDavid L Bushnell, Thomas M O'Dorisio, M Sue O'Dorisio, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Annals of Thoracic Surgery|February 16, 2002
Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?Kemp H Kernstine, Kelley A Mclaughlin, Yusuf Menda, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2019
NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATEThomas A Hope, Amanda Abbott, Karen Colucci, et al.
Pancreas|July 29, 2010
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and CecumJ Philip Boudreaux, David S Klimstra, Manal M Hassan, et al.
Pancreas|October 21, 2016
Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine TumorsNancy Sharma, Boris G Naraev, Eric G Engelman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 11, 2018
<sup>90</sup>Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide TherapyYusuf Menda, Mark T Madsen, Thomas M O'Dorisio, et al.
Pancreas|April 17, 2013
Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumorsYusuf Menda, Laura L Boles Ponto, Michael K Schultz, et al.
Pancreas|July 29, 2010
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreasMatthew H Kulke, Lowell B Anthony, David L Bushnell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2017
Localization of Unknown Primary Site with <sup>68</sup>Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine TumorYusuf Menda, Thomas M O'Dorisio, James R Howe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2021
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATEJonathan R Strosberg, Rajaventhan Srirajaskanthan, Ghassan El-Haddad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
90Y-edotreotide for metastatic carcinoid refractory to octreotideDavid L Bushnell, Thomas M O'Dorisio, M Sue O'Dorisio, et al.
Pageof 3